Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, we spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, we have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, we manage over $4.5 billion of committed capital.
LAV has significant resources in China, with extensive local expertise in preclinical and clinical development, regulatory knowhow, and market insights. We also have strong global perspective and connections, driven by the consolidated experience of our team members overseas as well as our network of scientific advisors. By combining our China expertise and global perspectives, we are uniquely positioned to support our portfolio companies and investors worldwide.
Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.
We bet on people. We are very selective, but when we find entrepreneurs with a unique combination of ambition, experience, leadership, and integrity, we are thrilled to support them with the long-term capital they need to succeed. In working with such exceptional entrepreneurs, we “first, do no harm”; where needed, we can bring significant value by helping make strategic decisions, recruit executives, secure industry contacts, and explore business development opportunities.
We also bet on products. We constantly ask ourselves “what will be the industry’s best-selling products 5-10 years from now?” and we find or build companies with such products. Our investment team remains up to date on global medical literature and clinical studies, as well as key opinion leader and industry expert insights.
At our core is a focus on quality science. LAV will not make an investment in low-quality products – we are not interested in “quick flip” investments built on hype. We will only make investments when attractive financial returns are aligned with the ethics of providing truly science-based, high-quality products to treat diseases and save lives.
Last but not the least, we are long-term thinkers. We are not driven by overnight success; instead, we are focused on building sustainable companies for the many decades ahead and catalyzing global medical innovations and humanity’s ever-increasing demand for better healthcare. This long-term thinking guides every investment decision, our organizational development, and the way we treat our partners.
Primarily in biopharmaceuticals, human therapeutics, medical devices, and diagnostics.
Core geographic focus is on China. We also increasingly invest in the U.S, especially for companies with a China angle.
We are stage-agnostic, and have invested in companies from seed stage to publicly-traded.